Evidence map›Paper›PMID 18802408›Full record

ArticleCell cycle (Georgetown, Tex.)2008

Phosphorylation of p53 on Ser15 during cell cycle caused by Topo I and Topo II inhibitors in relation to ATM and Chk2 activation.

Hong Zhao, Frank Traganos, Zbigniew Darzynkiewicz

Open access · bronzeAbstract read
In one paragraph

Article in Cell cycle (Georgetown, Tex.), 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 65 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. PAHSAs reduce cellular senescence and protect pancreatic beta cells from metabolic stress through regulation of Mdm2/p53.Proceedings of the National Academy of Sciences of the United States of America · 2022
    Article
  7. SMPDL3b modulates radiation-induced DNA damage response in renal podocytes.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2022
    Article
  8. Article
  9. Review
  10. International journal of molecular sciences · 2021
    Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Hong ZhaoBrander Cancer Research Institute and Department of Pathology, New York Medical College, Valhalla, New York 10595, USA.
Frank Traganos
Zbigniew Darzynkiewicz
New York Medical College · US

Funding

PROBES FOR FLOW CYTOMETRYR01CA028704 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI DARZYNKIEWICZ, ZBIGNIEW · 1985 to 2014
$6.0M
NCI NIH HHS CA 28704NCI NIH HHS R01 CA028704
6 · The paper itself

Abstract

The DNA topoisomerase I (topo1) inhibitor topotecan (TPT) and topo2 inhibitor mitoxantrone (MXT) damage DNA inducing formation of DNA double-strand breaks (DSBs). We have recently examined the kinetics of ATM and Chk2 activation as well as histone H2AX phosphorylation, the reporters of DNA damage, in individual human lung adenocarcinoma A549 cells treated with these drugs. Using a phospho-specific Ab to tumor suppressor protein p53 phosphorylated on Ser15 (p53-Ser15(P)) combined with an Ab that detects p53 regardless of the phosphorylation status and multiparameter cytometry we correlated the TPT- and MXT-induced p53-Ser15(P) with ATM and Chk2 activation as well as with H2AX phosphorylation in relation to the cell cycle phase. In untreated interphase cells, p53-Ser15(P) had "patchy" localization throughout the nucleoplasm while mitotic cells showed strong p53-Ser15(P) cytoplasmic immunofluorescence (IF). The intense phosphorylation of p53-Ser15, combined with activation of ATM and Chk2 (involving centrioles) as well as phosphorylation of H2AX seen in the untreated mitotic cells, suggest mobilization of the DNA damage detection/repair machinery in controlling cytokinesis. In the nuclei of cells treated with TPT or MXT, the expression of p53-Ser15(P) appeared as closely packed foci of intense IF. Following TPT treatment, the induction of p53-Ser15(P) was most pronounced in S-phase cells while no significant cell cycle phase differences were seen in cells treated with MXT. The maximal increase in p53-Ser15(P) expression, rising up to 2.5-fold above the level of its constitutive expression, was observed in cells treated with TPT or MXT for 4-6 h. This maximum expression of p53-Ser15(P) coincided in time with the peak of Chk2 activation but not with ATM activation and H2AX phosphorylation, both of which crested 1-2 h after the treatment with TPT or MXT. The respective kinetics of p53-Ser15 phosphorylation versus ATM and Chk2 activation suggest that in response to DNA damage by TPT or MXT, Chk2 rather than ATM mediates p53 phosphorylation.

Indexed as

DNA DamageTopoisomerase II InhibitorsTopoisomerase I InhibitorsAtaxia Telangiectasia Mutated ProteinsCell CycleCell Cycle ProteinsCell Line, TumorCheckpoint Kinase 2DNA-Binding ProteinsDNA Topoisomerases, Type IDNA Topoisomerases, Type IIEnzyme InhibitorsFluorescent Antibody TechniqueHumansMitoxantronePhosphorylationAtaxia Telangiectasia Mutated ProteinsATM protein, humanCell Cycle ProteinsCheckpoint Kinase 2CHEK2 protein, humanDNA-Binding ProteinsDNA Topoisomerases, Type IDNA Topoisomerases, Type IIEnzyme InhibitorsMitoxantroneProtein Serine-Threonine KinasesSerineTopoisomerase II InhibitorsTopoisomerase I InhibitorsTopotecanTumor Suppressor Protein p53Tumor Suppressor Proteins

Identifiers

PMID18802408
PMCPMC2577766
OpenAlexW1971884213

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.